Topiramate for Treating Cannabis Use Disorder in Adolescents with Bipolar Disorder
Author Information
Author(s): Jenni E. Farrow, Melissa P. DelBello, Luis R. Patino, Thomas J. Blom, Jeffrey A. Welge
Primary Institution: University of Cincinnati College of Medicine
Hypothesis
The study aims to evaluate the efficacy of adjunctive topiramate for the treatment of cannabis use disorder in adolescents with bipolar I disorder.
Conclusion
Topiramate is an effective treatment that reduces cannabis use and weight gain in adolescents with bipolar I disorder.
Supporting Evidence
- The TPM group showed a significant decrease in cannabis use compared to the placebo group.
- Participants in the TPM group experienced less weight gain than those in the placebo group.
- TPM was well-tolerated with manageable side effects.
Takeaway
This study shows that giving topiramate along with other treatments helps young people with bipolar disorder use less cannabis and gain less weight.
Methodology
The study was a 16-week, double-blind, randomized, placebo-controlled trial comparing topiramate plus quetiapine to quetiapine plus placebo.
Potential Biases
Potential bias due to the lack of diversity in the participant demographics.
Limitations
The study had a predominantly White sample, which may limit generalizability, and did not formally assess cognitive changes or ADHD symptoms over time.
Participant Demographics
Participants were adolescents aged 12-21, with a mean age of 17.4 years, predominantly White.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website